To include your compound in the COVID-19 Resource Center, submit it here.

Celgene reports Phase II data for Otezla in UC

Celgene Corp. (NASDAQ:CELG) reported data from a Phase II trial in 170 patients with active ulcerative colitis (UC) showing that twice-daily 30 and 40 mg doses of

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE